Contribution of Cytokines to Tissue Damage During Human Respiratory Syncytial Virus Infection

Abstract

The human respiratory syncytial virus (hRSV) remains one of the leading pathogens causing acute respiratory tract infections (ARTIs) in children younger than 2 years old, worldwide. Hospitalizations during the winter season due to hRSV-induced bronchiolitis and pneumonia increase every year. Despite this, there are no available vaccines to mitigate the health and economic burden caused by hRSV infection. The pathology caused by hRSV induces significant damage to the pulmonary epithelium, due to an excessive inflammatory response at the airways. Cytokines are considered essential players for the establishment and modulation of the immune and inflammatory responses, which can either be beneficial or harmful for the host. The deleterious effect observed upon hRSV infection is mainly due to tissue damage caused by immune cells recruited to the site of infection. This cellular recruitment takes place due to an altered profile of cytokines secreted by epithelial cells. As a result of inflammatory cell recruitment, the amounts of cytokines, such as IL-1, IL-6, IL-10, and CCL5 are further increased, while IL-10 and IFN-γ are decreased. However, additional studies are required to elicit the mediators directly associated with hRSV damage entirely. In addition to the detrimental induction of inflammatory mediators in the respiratory tract caused by hRSV, reports indicating alterations in the central nervous system (CNS) have been published. Indeed, elevated levels of IL-6, IL-8 (CXCL8), CCL2, and CCL4 have been reported in cerebrospinal fluid from patients with severe bronchiolitis and hRSV-associated encephalopathy. In this review article, we provide an in-depth analysis of the role of cytokines secreted upon hRSV infection and their potentially harmful contribution to tissue damage of the respiratory tract and the CNS.

Exploring active ingredients and function mechanisms of Ephedra-bitter almond for prevention and treatment of Corona virus disease 2019 (COVID-19) based on network pharmacology

“…Therefore, the intervention of ephedra-bitter almond on SARS-CoV-2 infected cells may also be carried out through the PI3K-Akt pathway. The excessive inflammatory response in the process of pathogen infection is destructive to the host, and when the production of pro-inflammatory cytokines increases, it causes serious damage to the lungs [ 66 ]. A study showed that IL-17 produced during viral infection specially enhanced the pro-inflammatory response by directly cooperating with antiviral signaling [ 67 ].…”

Inhibition of uric acid or IL‐1β ameliorates respiratory syncytial virus immunopathology and development of asthma

“…IL-1β is known to be a potent cytokine that amplifies the immune response through the activation of cytokine cascades as well as activation of critical innate immune cells, such as ILC2s. 18,19,35,36 Therefore, we decided to investigate the impact of IL-1βinduced immune activation on type 2 immunity-associated RSV immunopathology. To study the role of IL-1β during RSV infection, a neonatal murine model was utilized to recapitulate responses in clinical disease in infants ( Figure S1A).…”

Immunotherapy of COVID-19 with poly (ADP-ribose) polymerase inhibitors: starting with nicotinamide

“…The authors, however, did not observe a difference in viral load or increased IFN-β expression between wildtype and IDO KO mice and suggested that this mouse model does not reflect the human disease. Other studies with RSV patients did not report on IFN-β (which may not have been overexpressed), but observed enhanced expression of a wide array of cytokines and chemokines in the lower and upper respiratory tracts (see [ 38 ] for a review). Levels of IFN-β and IDO expression therefore need to be measured in COVID-19 patients.…”